Lead Product(s) : Diethylamide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
South Rampart Completes Phase 1 Study and Expands Phase 2 Plans
Details : SRP 3D (diethylamide) is a first-in-class non-opioid analgesic activating pain signaling pathways in the midbrain's periaqueductal grey. It’s in phase 1 trials for acute pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 02, 2024
Lead Product(s) : Diethylamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diethylamide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA)
Details : Diethylamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 02, 2022
Lead Product(s) : Diethylamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable